Skip to main content

Table 2 Studies of mesothelin as a prognostic biomarker

From: A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

Reference

n

Males (%)

Median age

Receiving CT (%)

ORR (%)

OS (months)

PFS (months)

Grigoriu et al. 2007 [13]

96

81

65

85

NR

m > 3.5 = 7.0

NR

m ≤ 3.5 = 19.0

P = 0.003

Cristaudo et al. 2007 [34]

107

83.2

69

NR

NR

m > 1 = 9.8

NR

m ≤ 1 = 21.5

P < 0.001

Creaney et al. 2011 [25]

97

89

66

69

 

m < 1 = 20.3

NR

m > 5 = 12.5

p = 0.01

Mori et al. 2013 [35]

26

21

5

26

19.2

m < 0.469* = 26.6

NR

m > 0.469* = 10.3

p = 0.027

This study

53

68

69

57**

m > 2.7 = 26

m > 2.7 = 11.3

m > 2.7 = 5.1

     

m ≤ 2.7 = 0

m ≤ 2.7 = 17.2

m ≤ 2.7 = 8.0

       

P = 0.059†

      

P = 0.088

 
  1. n = number patients; ORR, overall response rate; OS, median overall survival; PFS, mean progression free survival; NR, not reported; CT, chemotherapy; m, mesothelin level in nmol/L.
  2. *This study used the median mesothelin index, calculated by Log2 (mesothelin level after 2 courses of chemotherapy level/mesothelin level prior to chemotherapy). Assay specifically detected N-terminal 31 kDa fragment.
  3. **18 patients (34%) had a pre-chemotherapy mesothelin level and are therefore included in the response analysis.
  4. †If the PFS is analysed as a continuous variable for every unit increase the there is a HR of 1.03, p = 0.013.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us